Stifel Nicolaus upgraded shares of Aimmune Therapeutics (NASDAQ:AIMT) to a positive rating in a research note issued to investors on Monday morning, The Fly reports.

A number of other equities research analysts have also issued reports on the stock. Credit Suisse Group started coverage on shares of Aimmune Therapeutics in a research note on Tuesday, May 21st. They issued an outperform rating and a $30.00 target price on the stock. Roth Capital initiated coverage on shares of Aimmune Therapeutics in a research report on Friday, July 12th. They set a buy rating and a $45.00 price objective for the company. Wedbush set a $79.00 price objective on shares of Aimmune Therapeutics and gave the company a buy rating in a research report on Wednesday, August 21st. ValuEngine raised shares of Aimmune Therapeutics from a buy rating to a strong-buy rating in a research report on Wednesday, September 11th. Finally, BidaskClub downgraded shares of Aimmune Therapeutics from a buy rating to a hold rating in a research report on Saturday, August 24th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $42.13.

Shares of Aimmune Therapeutics stock opened at $22.79 on Monday. The firm has a market cap of $1.42 billion, a PE ratio of -6.21 and a beta of -0.09. The firm’s 50-day simple moving average is $20.57 and its 200-day simple moving average is $20.79. The company has a debt-to-equity ratio of 0.24, a quick ratio of 5.80 and a current ratio of 5.80. Aimmune Therapeutics has a 1 year low of $16.95 and a 1 year high of $36.12.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.08). During the same quarter last year, the business posted ($0.91) EPS. On average, equities analysts predict that Aimmune Therapeutics will post -4 earnings per share for the current year.

Large investors have recently made changes to their positions in the stock. Cable Hill Partners LLC grew its position in shares of Aimmune Therapeutics by 81.7% during the 1st quarter. Cable Hill Partners LLC now owns 1,112 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 500 shares during the last quarter. Manchester Capital Management LLC bought a new stake in shares of Aimmune Therapeutics during the 1st quarter valued at about $27,000. Marshall Wace North America L.P. bought a new stake in shares of Aimmune Therapeutics during the 1st quarter valued at about $32,000. Aperio Group LLC bought a new stake in shares of Aimmune Therapeutics during the 2nd quarter valued at about $76,000. Finally, Bank of Montreal Can grew its position in shares of Aimmune Therapeutics by 336.3% during the 2nd quarter. Bank of Montreal Can now owns 4,363 shares of the biotechnology company’s stock valued at $90,000 after buying an additional 3,363 shares during the last quarter. 78.06% of the stock is owned by institutional investors and hedge funds.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

Featured Story: What Are Treasury Bonds?

The Fly

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.